NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and Qiagen Manchester Ltd., a wholly owned subsidiary of Qiagen, said today that they have inked a master assay development, commercialization, and manufacturing agreement.

The agreement creates a framework for the companies to combine their technological and commercial strengths to offer pharmaceutical companies a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests, with a focus on oncology.